September 19, 2022 09:08 AM EDTUpdated 10:19 AM
R&D
Pharma

First the US, now the EU: Pfiz­er’s 20-va­lent pneu­mo­coc­cal jab for in­fants head­ed to reg­u­la­tors 

Kyle LaHucik

Senior Reporter

About five weeks af­ter Pfiz­er said its 20-va­lent vac­cine fol­low-up to Pre­vnar 13 was ef­fec­tive in in­fants in a US study, the Big Phar­ma now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times